The FDA approved the first biosimilar in the U.S. in March of 2015 with more expected to be approved in 2016. Now, on a state by state basis, the laws that govern how these new therapies can be dispensed are being updated. Arizona has the opportunity to do so in 2016 with HB 2310 sponsored by Dr. Regina Cobb, Vice Chairman of the House Health Committee.Continue reading
Category Archives: Government Affairs Blog
Congress Suspends The Medical Device Tax for Two Years
Medical device innovators got good news on December 18th as Congress passed a two-year moratorium on a tax the industry said was limiting its growth. Companies and industry backers in Arizona and around the country have worked for years to repeal the 2.3 percent tax on revenue from medical device sales. Continue reading
AdvaMedDx Issues Statement on House Diagnostic Test Hearing
Washington Update – October and November 2015
The Washington Update for CSBA is provided to AZBio Members as an update on issues that affect our industry at the nation’s capitol
Continue reading
AZBio Honors Ten Arizona Legislators as 2015 Trailblazers
AZBio Trailblazers are selected annually and recognized for their leadership in supporting research, education, innovation and the growth of Arizona’s bioscience sector by the Arizona Bioindustry Association.Continue reading
Washington Update
The latest updates from Capitol Hill as provided by BIO and Republic Consulting Group.Continue reading
AdvaMed’s Steve Ubl Announces Move to PhRMA
Steve Ubl, president and CEO of AdvaMed will leave his post at AdvaMed in the fall to serve as president and CEO of PhRMA.
Ubl shared the letter below with the AdvaMed Board of Directors on Friday, September 25, 2015.Continue reading
Washington Update – Fall Preview
The latest updates from Capitol Hill as provided by BIO and Republic Consulting Group.
Continue reading